Keyphrases
Therapeutic Monoclonal Antibody
47%
COVID-19
46%
Monoclonal Antibody
35%
Rapid Test
27%
Telehealth
27%
Rapid Antigen Test
27%
BinaxNOW
27%
Coronavirus Disease (COVID)
27%
Free State
27%
Self-referral
27%
Mass Testing
27%
Postpoliomyelitis Syndrome
27%
Post-poliomyelitis Syndrome
27%
Treatment Timing
27%
Solid Organ Transplant Recipients
27%
Bebtelovimab
27%
COVID-19 Outcomes
27%
Infusion Treatment
27%
Racial Disparities
27%
COVID-19 Education
27%
Hesitancy
27%
Future Pandemics
27%
African American Patients
13%
Single Center
10%
Underutilization
10%
Emergency Use Authorization
6%
Inequity
6%
Treatment Eligible
6%
Infusion Center
6%
Novel Therapeutics
6%
White Patients
6%
Dominant Period
5%
Medicine and Dentistry
COVID-19
100%
Monoclonal Antibody
37%
Infusion
34%
Clinician
27%
Rapid Test
27%
Severe Acute Respiratory Syndrome Coronavirus 2
27%
Telehealth
27%
Monoclonal Antibody Therapy
27%
Patient Referral
27%
Pandemic
27%
Racial Disparity
27%
Pediatrics
18%
Reverse Transcription Polymerase Chain Reaction
18%
Omicron Coronavirus Variant
13%
Symptom
9%
Sensitivity and Specificity
9%
Cross Sectional Study
6%
Nursing and Health Professions
Monoclonal Antibody
27%
Rapid Test
27%
Predictive Value
27%
Patient Referral
27%
Clinician
27%
Postpoliomyelitis Syndrome
27%
Telehealth
27%
Diseases
27%
Severe Acute Respiratory Syndrome
16%
Disease
11%
Sensitivity and Specificity
9%
Reverse Transcription Polymerase Chain Reaction
7%
Infusion
6%
